RORA Biologics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 5

RORA Biologics General Information

Description

Developer of a T-cell platform designed to provide innovative cell therapies, including genetically engineered chimeric antigen receptor T cells, to treat cancer patients. The company's platform offers recently discovered stem cell-like memory T cells to make chimeric antigen receptor drugs more durable, safer, and long-lasting, along with a stand-alone therapy to reconstitute the immune system affected by human immunodeficiency virus infection, enabling healthcare professionals to improve treatment for patients.

Contact Information

Website
www.rorabio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2260 Lenox Walk
  • Brookhaven
  • Atlanta, GA 30319
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 2260 Lenox Walk
  • Brookhaven
  • Atlanta, GA 30319
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

RORA Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 23-Dec-2025 Completed Pre-Clinical Trials
3. Early Stage VC 01-Jun-2024 Completed Pre-Clinical Trials
2. Early Stage VC 01-Jan-2023 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2021 Completed Pre-Clinical Trials
To view RORA Biologics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

RORA Biologics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

RORA Biologics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Gaingels Venture Capital Minority
Georgia Research Alliance Not-For-Profit Venture Capital Minority
Ventac Partners Venture Capital Minority
Case Western Reserve University University
Emory University University
To view RORA Biologics’s complete investors history, request access »

RORA Biologics FAQs

  • When was RORA Biologics founded?

    RORA Biologics was founded in 2021.

  • Where is RORA Biologics headquartered?

    RORA Biologics is headquartered in Atlanta, GA.

  • What is the size of RORA Biologics?

    RORA Biologics has 4 total employees.

  • What industry is RORA Biologics in?

    RORA Biologics’s primary industry is Drug Discovery.

  • Is RORA Biologics a private or public company?

    RORA Biologics is a Private company.

  • What is RORA Biologics’s current revenue?

    The current revenue for RORA Biologics is .

  • Who are RORA Biologics’s investors?

    Gaingels, Georgia Research Alliance, Ventac Partners, Case Western Reserve University, and Emory University have invested in RORA Biologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process